CSL Akcija

CSL P/CF

Delisted·2026. g. 19. jūn.

P/CF (Cenas-naudas plūsmas koeficients) no CSL (CSL.AX) uz 2026. g. 6. aug. ir 13,33. Iepriekšējā gadā P/CF (Cenas-naudas plūsmas koeficients) bija 17,17 — izmaiņas -22,38 % (zemāks).

P/CF

13,33

YoY

-22,38%

Pēdējoreiz atjaunināts:

P/CF (Cenas-naudas plūsmas koeficients) no CSL ir 2026 13,33 . P/CF (Cenas-naudas plūsmas koeficients) no CSL bija 2025 17,17 . Tas samazinās par -22,38% zemāks salīdzinājumā ar iepriekšējo gadu.
Access this data via the Eulerpool API

CSL Akciju analīze

Ko dara CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL ir viens no populārākajiem uzņēmumiem Eulerpool.

Bieži uzdotie jautājumi par CSL akciju

CSL P/CF (Cenas-naudas plūsmas koeficients) 2026. gadā ir 13,33.

P/CF (Cenas-naudas plūsmas koeficients) no CSL mainījās no 17,17 uz 13,33, kas atspoguļo -22,38 % izmaiņas. Vērtība ir zemāks nekā iepriekšējā gadā.

Vietnē Eulerpool varat atrast pilnīgu P/CF (Cenas-naudas plūsmas koeficients) CSL vēsturisko attīstību kopš 2006. gada — ar gada vērtībām, grafikiem un detalizētu analīzi.

Cenas un naudas plūsmas koeficients mēra akciju cenu attiecībā pret darbības naudas plūsmu uz akciju.

P/CF = Akcijas cena / Operatīvā naudas plūsma uz akciju

Salīdziniet rādītājus ar nozares vidējiem rādītājiem, jo standarti ievērojami atšķiras. Piemēram, mazumtirdzniecības maržas parasti ir zemākas nekā programmatūras maržas.

Laba vērtība ir atkarīga no nozares, ekonomikas cikla un uzņēmuma stratēģijas. Vienmēr salīdziniet ar uzņēmuma vēsturiskajām vērtībām un konkurentu etalonu rādītājiem.

Access this data via the Eulerpool API

Novērtēšana — CSL

Visas kategorijas